Why Tesla Motors, Dendreon, and Intercept Pharmaceuticals Tumbled Today

Stocks were mixed Thursday on a volatile day for the market. But these three stocks took big losses on the day. Find out why.

May 8, 2014 at 8:35PM

The stock market nixed hopes that it would rise to unprecedented highs on Thursday, but investors still fared relatively well, with the major market benchmarks delivering mixed results after giving up much larger gains earlier in the day. Yet certain stocks continued to face significant pressure to put up strong fundamental performance; on that score, Tesla Motors (NASDAQ:TSLA), Dendreon (NASDAQ:DNDN), and Intercept Pharmaceuticals (NASDAQ:ICPT) failed to deliver and were punished.

Source: Tesla Motors.

Tesla Motors fell 11% despite posting what many saw as strong first-quarter results. Revenue for the electric car-maker jumped more than 26% to $713 million, and adjusted earnings per share did better than investors had expected. Yet deliveries of Model S electric vehicles came in only marginally above Tesla's original quarterly forecast, and that disappointed investors who have become accustom to seeing Tesla crush its own past guidance in its actual report. Yet many things are going right at Tesla, as production rates climb steadily and make the company's goal of 35,000 deliveries for 2014 realistically achievable. Moreover, with its gigafactory battery-production facility starting to take shape, Tesla seems to be meeting all of its long-term goals even as its shares suffer a short-term bump in the road.


Source: Steven Depolo, Flickr.

Dendreon dropped 13% after the biotech producer of prostate cancer drug Provenge reported fresh quarterly results. Revenue climbed less than 2%, and even though Dendreon managed to cut its year-ago loss in half, Provenge sales have had to fight just to stay stable in the face of competition from rivals. Although cost-cutting moves have helped improve Dendreon's bottom line, the secret to long-term success lies with Provenge, and few investors believe the drug has much upside left. That could bode ill for the future prospects for Dendreon's stock, and several analysts followed up the company's report with downgrades.

Intercept Pharmaceuticals declined 13%, also in response to its earnings release last night. The biotech's net loss soared from the year-ago level due almost exclusively to the repricing of stock warrants, but rising research and development expenses also took a toll on profitability. Yet with all warrants having been converted into stock, Intercept Pharmaceuticals should have recorded its last noncash charge connected to the securities. With enough cash to fund operations until 2016, Intercept Pharmaceuticals is in a good position to let its treatments do the talking without fear of needing dilutive financing. The big question is whether its development-stage liver-disease treatments will make it through clinical testing and prove themselves as FDA-approved drugs at some point in the future. Although Intercept Pharmaceuticals has plenty of potential, investors still have to look critically at the company after its recent share-price surge.

Warren Buffett just bought nearly 9 million shares of this company
Imagine a company that rents a very specific and valuable piece of machinery for $41,000... per hour (that's almost as much as the average American makes in a year!). And Warren Buffett is so confident in this company's can't-live-without-it business model, he just loaded up on 8.8 million shares. An exclusive, brand-new Motley Fool report details this company that already has over 50% market share. Just click HERE to discover more about this industry-leading stock... and join Buffett in his quest for a veritable landslide of profits!

Dan Caplinger has no position in any stocks mentioned. The Motley Fool recommends Tesla Motors. The Motley Fool owns shares of Tesla Motors. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers